Nucala subcutaneous injection 100mg syringe (YJ code: 2290401G1026, standard: 100mg 1mL 1 tube) is a GlaxoSmithKline medication containing Mepolizumab (genetical recombination). It is indicated for add-on maintenance treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and adolescents aged 12 years and older.
Nucala subcutaneous injection 100mg syringe
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →